表紙
市場調查報告書
商品編碼
980135

選擇性雌激素受體降解劑(SERD):市場,劑量,價格,臨床試驗考慮因素(∼2025)

Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025

出版日期: | 出版商: KuicK Research | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

到2025年,選擇性雌激素受體降解劑(SERD)的全球市場預計將超過20億美元。預計在未來幾年中,全球SERD市場將以兩位數的複合年增長率增長。據估計,治療藥物市場的主要驅動力是美國和新興市場。

當前治療藥物市場的研發渠道以驚人的速度增長,市場成功率以歷史水平加速增長,使其成為未來幾年潛在的藥物候選者。發射的數量將增加。隨著市場品牌的顯著增長,選擇性雌激素受體療法市場上批准的未來新產品有望為顯著的淨銷售額和創收做出貢獻。

本報告調查了選擇性雌激素受體降解藥物(SERD)市場,按公司,國家,適應症和患者分類以及品牌和非專利藥物的劑量,價格和價格考慮了臨床流程,為銷售提供了見解。以及商業和臨床機會。

目錄

第1章選擇性雌激素受體降解劑(SERD)簡介

  • 概述
  • SERD的演變

第2章選擇性雌激素受體降解劑:作用機理

第3章選擇性雌激素受體抑制劑作為聯合療法

  • CDK4/6抑制劑和SERD的組合
  • PI3K抑制劑和SERD的組合
  • 芳香化□抑制劑和SERD的組合
  • mTOR抑制劑和SERD的組合

第4章SERD在癌症治療中的作用

第5章乳腺癌中選擇性雌激素受體降解藥物

  • SERD對乳腺癌治療的作用
  • 正在進行的研發
    • AZD 9833
    • Rintodestrant(G1T48)
    • ZN-c5
    • Elacestrant(RAD1901)
    • LSZ 102
    • OP-1250
    • LY3484356
    • GDC-9545(RG6171)
    • SHR9549
    • AZD9496

第6章選擇性雌激素受體降解藥物市場分析

  • 當前市場情況
  • COVID-19對選擇性雌激素受體降解藥物市場的影響
  • 市場機會

第7章選擇性雌激素受體降解劑:市場趨勢

  • Zentalis Pharma與Eli Lily合作評估SERD和CDK 4/6抑制劑組合
  • Olema Oncology&Novartis宣佈臨床合作以評估SERD作為聯合治療
  • 新的SERD聯合療法對HR +/HER2陰性乳腺癌顯示出可喜的結果
  • Radius和Menarini合作開發軟化劑並將其商業化
  • SERD組合可靶向神經纖維瘤病基因治療乳腺癌

第8章選擇性雌激素受體降解藥物(SERD)抑製劑的臨床試驗概述

  • 按公司
  • 指示
  • 按患者細分
  • 按階段

第9章考慮選擇性雌激素受體降解藥物(SERD)的臨床試驗

  • 臨床前
  • 第一階段
  • 第一階段/第二階段
  • 第二階段
  • 第三階段

第10章考慮非處方雌激素受體降解劑(SERD):助溶劑

第11章Faslodex(氟維司群):非處方選擇性雌激素受體抑製劑

  • 批准和專利糾紛
  • 價格和劑量分析
  • 銷售分析
  • Faslodex:兌換場景

第12章助劑泛型:可用性和價格分析

  • Fulviglen
  • Fulvenat
  • Fulvetraz
  • Fuvesterol
  • Strantas
  • Celvestrant
  • Faslomax
  • Fasnorm

第13章競爭情況

  • AsteraZeneca
  • Eli Lilly
  • G1 Therapeutics
  • Novartis
  • Olema Oncology
  • Radius Therapeutics
  • Roche
  • Sage Therapeutics
  • Zeno Pharma
  • Zentalis
目錄

"Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:

  • Global SERD Market Opportunity: > US$ 2 Billion By 2025
  • USA To dominate Global SERD Market
  • SERD In Clinical Trials: > 15 Drugs
  • Detailed Clinical insight on All Drugs in clinical Trials
  • Clinical Pipeline Insight by Company, Country, Indication & Patient Segment
  • Branded & Generic Drug Dosage, Price & Sales Insight
  • 150 Page Report: Commercial & Clinical Opportunity Insight

The research report, "Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025" provides detailed insight on clinical and non clinical parameters involved in the development and expansion of the global SERD market. In addition to it, the research report also describes the impact of novel drug launches on the other available therapies for breast cancer as well as growth rate of the specific drugs available under the therapy. Other than the market forecast, the research report also highlights the future trends and opportunities that will highly impact the use of expensive drugs for the treatment of breast cancer. Some of the areas that are highlighted in the research report involves the market fragmentation based on the real-world evidence of the therapy at clinical and pre-clinical level.

The global selective estrogen receptor degrader therapy market is witnessed to exceed by a double-digit CAGR rate over the next few years, which will positively impact the other commercially available therapies and cause a notable slowdown in their market growth rate. The major key drivers for the therapy market are estimated to be the US market as well as emerging markets upto some extent, which in the future years will also continue to be the major drivers for the market. The current research and development pipeline for the therapy market is growing at a splendid rate, and the success rate for the market are accelerating at historic level, thus resulting in more launches of potential candidates in the upcoming years. The future novel products approved under selective estrogen receptor degrader therapy market are believed to contribute a large net sales and revenue generation, as the market brand will grow at extensive rate.

The current market is observed to lift the share of the oncology sector to the global pharmaceutical market to new extent, which will continue to increase with time. In addition to it, the overall market at global level has also observed a large influx in the number of market players and government initiatives so that large number of patients could receive benefits from such selective cancer therapy. The highly advanced satisfactory applications and benefits received from the therapy is believed to expand the market to become one standard care for patients suffering from breast cancer.

As per the research conducted for Global selective estrogen receptor degrader therapy market, it is estimated that the therapy when compared with other commercially available therapies can provide maximum potential returns to the breast cancer patients in terms of healthcare benefits as well as to the investors and bio-pharmaceutical companies in terms of total sales and revenue generation. The market due to strong and robust clinical pipeline is also brewing up to become more independently and economically strong. It is observed for the market, that the long-term healthcare benefits available will push the researchers towards conducting more complex clinical research studies in order to generate more applications for the breast cancer patients.

Table of Contents

1. Introduction to Selective Estrogen Receptor Degraders (SERDs)

  • 1.1 Overview
  • 1.2 Evolution of SERDs

2. Selective Estrogen Receptor Degraders - Mechanism of Action

3. Selective Estrogen Receptor Inhibitors as Combinational Therapy

  • 3.1 SERD with CDK 4/6 Inhibitors
  • 3.2 SERD with PI3K Inhibitors
  • 3.3 SERD with Aromatase Inhibitors
  • 3.4 SERDs with mTOR Inhibitors

4. Role of SERDs in Cancer Treatment

5. Selective Estrogen Receptor Degraders in Breast Cancer

  • 5.1 Impact of SERDs in Breast Cancer Treatment
  • 5.2 Ongoing Research & Development
    • 5.2.1 AZD 9833
    • 5.2.2 Rintodestrant (G1T48)
    • 5.2.3 ZN-c5
    • 5.2.4 Elacestrant (RAD1901)
    • 5.2.5 LSZ 102
    • 5.2.6 OP-1250
    • 5.2.7 LY3484356
    • 5.2.8 GDC-9545 (RG6171)
    • 5.2.9 SHR9549
    • 5.2.10 AZD9496

6. Selective Estrogen Receptor Degrader Market Analysis

  • 6.1 Current Market Scenario
  • 6.2 Impact of COVID-19 on Selective Estrogen Receptor Degrader Market
  • 6.3 Market Opportunity

7. Selective Estrogen Receptor Degrader - Market Trends

  • 7.1 Zentalis Pharma Collaborated with Eli Lily to Evaluate the Combination of SERD with CDK4/6 Inhibitors
  • 7.2 Olema Oncology & Novartis Announces Clinical Collaboration to Evaluate SERD as Combinational Therapy
  • 7.3 New SERD Combinational Therapy Shows Promising Results against HR+/HER2 Negative Breast Cancer
  • 7.4 Radius & Menarini Collaborates for Development & Commercialization of Elacestrant
  • 7.5 SERD Combination Can Target the Neurofibromatosis Gene for Treating Breast Cancer

8. Selective Estrogen Receptor Degrader (SERD) Inhibitors Clinical Trials Overview

  • 8.1 By Company
  • 8.2 By Indication
  • 8.3 By Patient Segment
  • 8.4 By Phase

9. Selective Estrogen Receptor Degrader (SERD) Clinical Trials Insight

  • 9.1 Preclinical
  • 9.2 Phase-I
  • 9.3 Phase-I/II
  • 9.4 Phase-II
  • 9.5 Phase-III

10. Marketed Selective Estrogen Receptor Degrader (SERD) Insight: Fulvestrant

11. Faslodex (Fulvastrant)- Commercially Available Selective Estrogen Receptor Inhibitor Drug

  • 11.1 Approval & Patent Dispute
  • 11.2 Pricing & Dosage Analysis
  • 11.3 Sales Analysis
  • 11.4 Faslodex - Reimbursement Scenario

12. Generic Fulvestrant - Availability & Price Analysis

  • 12.1 Fulviglen
  • 12.2 Fulvenat
  • 12.3 Fulvetraz
  • 12.4 Fuvesterol
  • 12.5 Strantas
  • 12.6 Celvestrant
  • 12.7 Faslomax
  • 12.8 Fasnorm

13. Competitive Landscape

  • 13.1 AsteraZeneca
  • 13.2 Eli Lilly
  • 13.3 G1 Therapeutics
  • 13.4 Novartis
  • 13.5 Olema Oncology
  • 13.6 Radius Therapeutics
  • 13.7 Roche
  • 13.8 Sage Therapeutics
  • 13.9 Zeno Pharma
  • 13.10 Zentalis

List of Figures

  • Figure 1-1: Evolution of SERDs Drugs
  • Figure 2-1: Role of Estrogen Receptor in Tumor Development
  • Figure 2-2: Mechanism of Selective Estrogen Receptor Degraders
  • Figure 2-3: Mechanism of SERDs in Combination with other Cancer Therapeutics
  • Figure 3-1: CDK 4/6 Inhibitors Used in Combination with SERDs
  • Figure 3-2: PI3K Inhibitors Used in Combination with SERDs
  • Figure 3-3: Aromatase Inhibitors Used in Combination with SERDs
  • Figure 4-1: Global - Breast Cancer Cases by Nature of Estrogen Receptor (%), 2020
  • Figure 4-2: Role of SERDs in Cancer Management
  • Figure 5-1: Global - Newly Diagnosed Cases & Deaths related to Breast Cancer (Million), 2020
  • Figure 5-2: Global - Breast Cancer Cases by Type (Million), 2020
  • Figure 5-3: Investigational SERDs Candidates & Their Manufacturers
  • Figure 5-4: SERENA-2 Trial - Study Initiation & Expected Completion Year For Primary Breast Cancer
  • Figure 5-5: SERENA-2 Trial - Study Initiation & Expected Completion Year for Advanced Breast Cancer
  • Figure 5-6: SERENA-1 Trial - Study Initiation & Expected Completion Year
  • Figure 5-7: AZD9833 Japan Trial - Study Initiation & Expected Completion Year
  • Figure 5-8: Rintodestrant Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 5-9: ZN-c5 Monotherapy Trial - Study Initiation & Expected Completion Year
  • Figure 5-10: ZN-c5/Abemaciclib Combination Trial- Study Initiation & Expected Completion Year
  • Figure 5-11: ZN-c5/ Palbociclib Trial- Study Initiation & Expected Completion Year
  • Figure 5-12: Elacestrant Phase 3 Trial- Study Initiation & Expected Completion Year
  • Figure 5-13: Elacestrant - Study Initiation & Completion Year
  • Figure 5-14: LSZ102 Phase I/II Trial- Study Initiation & Completion Year
  • Figure 5-15: OP-1250 Phase I/II Trial - Study Initiation & Completion Year
  • Figure 5-16: EMBER-2 Trial - Study Initiation & Expected Completion Year
  • Figure 5-17: LY3484356 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 5-18: GDC-9545 Phase I Trial- Study Initiation & Expected Completion Year
  • Figure 5-19: GDC-9545/Fulvestrant Combinational Trial - Study Initiation & Expected Completion Year
  • Figure 5-20: SHR 9549 Phase I Trial - Study Initiation & Completion Year
  • Figure 6-1: Global - SERD Market Size (US$ Million), 2016 - 2020
  • Figure 6-2: Global - SERD Market Size by Type of Product (US$ Million), 2019
  • Figure 6-3: Global - SERD Market Size by Type of Product (%), 2019
  • Figure 6-4: Global - Number of Pharmaceutical Organization Impacted by COVID-19 by Intensity, 2020
  • Figure 6-5: Global - Number of Pharmaceutical Organization Impacted by COVID-19 by Intensity (%), 2020
  • Figure 6-6: Global - Estimated Breast Cancer Cases (Million), 2020, 2025 & 2030
  • Figure 6-7: Global - Estimated Breast Cancer Cases (Million), 2020, 2025 & 2030
  • Figure 6-8: Global - Estimated ER Positive Breast Cancer Cases (Million), 2020, 2025 & 2030
  • Figure 6-9: Global - SERD Market Opportunity (US$ Billion), 2020 - 2025
  • Figure 6-10: US - SERD Market Opportunity (US$ Million), 2020 - 2025
  • Figure 6-11: Europe - SERD Market Opportunity (US$ Million), 2020 - 2025
  • Figure 8-1: SERD - Clinical Trials by Company (Number of Drugs), 2020 - 2025
  • Figure 8-2: SERD - Clinical Trials by Indication (Number of Drugs), 2020 - 2025
  • Figure 8-3: SERD - Clinical Trials by Patient Segment (Number of Drugs), 2020 - 2025
  • Figure 8-4: SERD - Clinical Trials by Phase (Number of Drugs), 2020 - 2025
  • Figure 11-1: Faslodex - FDA Approval Year by Type of Breast Cancer
  • Figure 11-2: Faslodex - FDA Approval Year & First Generic Approval Year
  • Figure 11-3: Faslodex - Patent Issue & Expiration Year
  • Figure 11-4: Faslodex - Price for 10 ml & Price per ml of Intramuscular Injection (US$), January'2021
  • Figure 11-5: Faslodex - Recommended & Reduced Dose (mg)
  • Figure 11-6: Faslodex - Number of Doses by Treatment Phase
  • Figure 11-7: Faslodex - Cost For First & Subsequent Treatment Cycle (US$)
  • Figure 11-8: Global - Faslodex Annual Sales Value (US$ Million), 2016 - 2019
  • Figure 11-9: Global - Faslodex Annual Sales Values (US$ Million), 2002 - 2015
  • Figure 11-10: Global - Faslodex Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 11-11: US - Faslodex Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 11-12: Europe - Faslodex Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 11-13: Global - Faslodex Annual Sales Value by Region (US$ Million), 2019
  • Figure 11-14: Global - Faslodex Annual Sales Value by Region (%), 2019
  • Figure 11-15: Global - Faslodex Quarterly Sales Value (US$ Million), Q1 - Q3, 2020
  • Figure 11-16: Global - Faslodex 9 Month Sales Value by Region (US$ Million), 2020
  • Figure 11-17: Global - Faslodex 9 Month Sales Value by Region (%), 2019
  • Figure 11-18: US - Faslodex Quarterly Sales Value (US$ Million), Q1 - Q3, 2020
  • Figure 11-19: Europe - Faslodex Quarterly Sales Value (US$ Million), Q1 - Q3, 2020
  • Figure 11-20: US - Typical Co-Pay Range of Branded & Generic Fulvestrant (US$), January'2021
  • Figure 12-1: Fulviglen - Price for a Supply of 3 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-2: Fulviglen - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-3: Fulviglen - Price for a Supply of 9 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-4: Fulvenat - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-5: Fulvenat - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-6: Fulvenat - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-7: Fulvetraz - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-8: Fulvetraz - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-9: Fulvetraz - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-10: Fuvesterol - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-11: Fuvesterol - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-12: Fuvesterol - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-13: Strantas - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-14: Strantas - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-15: Strantas - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-16: Celvestrant - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-17: Celvestrant - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-18: Celvestrant - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-19: Faslomax - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-20: Faslomax - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-21: Faslomax - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-22: Fasnorm - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-23: Fasnorm - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-24: Fasnorm - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021